Sun Pharmaceutical Industries Limited
Credit Rating
01 / The disclosure
What the company shared
Sun Pharmaceutical Industries Limited has informed the Exchange about Credit Rating
A question for your research
Check the authority, amount, company response and appeal status. A notice and a final liability are different stages.
Numbers found in document text 1 matches
Automatic text matches, not verified financial metrics. A match may come from a table heading or reporting year. Expand it to inspect the surrounding text and original page.
INR 150 crorePage 1
Further, ICRA has reaffirmed its rating of [ICRA]A1+ reaffirmed to the short-term fund-based/non-fund- based facilities aggregating INR 150 crore of Sun Pharma Laboratories Limited ("SPLL"), a wholly-owned subsidiary of the Company.
View source pageThe evidence
Read the source excerpts
01Intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 – Update on Credit Ratings
Page 1
02Pursuant to Regulation 30 read with Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, this is to inform that CRISIL Ratings Limited ("CRISIL") and ICRA Limited ("ICRA") have assigned ratings to the proposed Non-Convertible Debenture ("NCD") programme of Sun Pharmaceutical Industries Limited ("Company") and reaffirmed the ratings assigned to the existing facilities of the Company.
Page 1
03Rating Agency Instrument/Type Rating CRISIL Non-Convertible Debentures Crisil AAA/Stable (Assigned) Commercial Paper Crisil A1+ (Reaffirmed) Long Term Rating Crisil AAA/Stable (Reaffirmed) Short Term Rating Crisil A1+ (Reaffirmed) ICRA Non-Convertible Debentures [ICRA]AAA (Stable) assigned Commercial Paper [ICRA]A1+ reaffirmed Long-term short-term, fund-based/ non- fund-based limits [ICRA]AAA (Stable)/ [ICRA]A1+ reaffirmed
Page 1
04As stated in the respective rating communications, the ratings factor in, inter alia, the Company's strong business and financial profile and also take into consideration the proposed acquisition of Organon & Co.
Page 1
05Further, ICRA has reaffirmed its rating of [ICRA]A1+ reaffirmed to the short-term fund-based/non-fund- based facilities aggregating INR 150 crore of Sun Pharma Laboratories Limited ("SPLL"), a wholly-owned subsidiary of the Company.
Page 1
Source & verificationView the disclosure trail
- Summary method
- Exchange-provided text; no generated financial figures
- Exchange identifier
- 106816165
- First collected
- 13 Oct 2026, 17:55 IST
- PDF extraction
- extracted · 1 pages read
- Extraction note
- Source excerpts; financial tables have not been validated.
- Document SHA-256
- 15f447bafbf277441f134e1d88de4fe7abef08075f95cff9af357f0a08932011